<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114097</url>
  </required_header>
  <id_info>
    <org_study_id>H-18064175</org_study_id>
    <nct_id>NCT04114097</nct_id>
  </id_info>
  <brief_title>The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover</brief_title>
  <official_title>The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacob Thyssen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators believe that the emerging epidemiological evidence connecting topical use
      of corticosteroids to the development of type 2 diabetes and osteoporosis point to
      potentially massive, yet clinically unacknowledged problems associated with topical
      corticosteroid treatment. Using state-of-the-art methodology, the present study will
      delineate the impact of topical corticosteroid use on insulin sensitivity and bone turnover
      markers in patients with atopic dermatitis and, thus, provide important data that may have
      implications for millions of people using topical corticosteroids.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomised, two-arm, active comparator, double-dummy, double-blinded trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in whole-body insulin sensitivity</measure>
    <time_frame>Baseline, after 14 days daily treatment, and after 4 weeks of twice daily treatment twice weekly</time_frame>
    <description>Change in whole-body insulin sensitivity during treatment with topical corticosteroid use compared to the control group treated with topical calcineurin inhibitors. Insulin sensitivity will be assessed by the hyperinsulinaemic euglycaemic clamp method with glucose and glycerol tracer and indirect calorimetry (rate of disappearance (Rd)).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Atopic Eczema</condition>
  <arm_group>
    <arm_group_label>Betamethasone-17-valerat + placebo ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid (&quot;Betnovate&quot;, betamethasone dipropionate ointment 0.1%) and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing calcineurin inhibitor (&quot;Protopic&quot;, tacrolimus ointment 0.1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betnovate, betamethasone dipropionate ointment 0.1% and placebo</intervention_name>
    <description>Explore the systemic effects of Betnovate</description>
    <arm_group_label>Betamethasone-17-valerat + placebo ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Protopic, tacrolimus ointment 0.1%</intervention_name>
    <description>Compare the systemic effects of Betnovate to Protopic</description>
    <arm_group_label>Tacrolimus ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age 18-75 years

          -  AD according to the Hanifin and Rajka Criteria24

          -  AD for at least 3 years

          -  BMI ≤ 30 kg/m2

          -  Haemoglobin A1c (HbA1c) ≤ 42 mmol/mol (6.0%)

          -  Normal haemoglobin (men: 8.3-10.5 mmol/L and women 7.3-9.5 mmol/L. A 5% deviation will
             be allowed if the patient besides this is healthy)

          -  Informed consent

          -  In general patients should not be diagnosed with diseases that may affect or be
             affected by the study/treatment (evaluated by a doctor) (such as untreated skin
             infections, acne vulgaris (beside face region), a skin barrier defect, such as
             Netherton's syndrome, lamellar ichthyosis, generalized erythroderma or cutaneous Graft
             Versus Host Disease, congenital or acquired immunodeficiencies or in patients on
             therapy that cause immunosuppression, and Protopic ointment should not be applied to
             lesions that are considered to be potentially malignant or pre-malignant. Further
             patients should not suffer from kidney or liver disease/insufficiency. See the SPC for
             Protopic and Betnovate.)

        Exclusion criteria

          -  Diagnosed diabetes mellitus

          -  Other chronic inflammatory diseases (including but not limited to rheumatoid
             arthritis, inflammatory bowel disease etc) beside AD and non-treatment demanding
             rhinitis or asthma (treated within the last 4 weeks)

          -  Pregnancy (a urine test will be done at every visit and birth control is required, see
             below*)

          -  Breast feeding

          -  Treatment with drugs that might affect the glucose metabolism beside TCS within a
             month prior to the project

          -  Daily smoker, alcoholic, or drug abuser

          -  Hypersensitivity to Protopic or Betnovate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob P Thyssen, Professor, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology and Allergy, Gentofte Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Gether, MD</last_name>
    <phone>+4591175147</phone>
    <email>lise.gether.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Dermatology and Allergy</name>
      <address>
        <city>Hellerup</city>
        <state>Region Hovedstaden</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hudsygdomme Klinik</last_name>
      <phone>+4538673211</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Jacob Thyssen</investigator_full_name>
    <investigator_title>Professor, consultant</investigator_title>
  </responsible_party>
  <keyword>topical corticosteroids</keyword>
  <keyword>topical calcineurin inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

